<DOC>
	<DOCNO>NCT00791193</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetics relative bioavailability paliperidone ER formulation slow , target , fast vitro release rate administration single 12 mg dose . The slow fast release ER tablet vitro release rate outside current commercial specification . Therefore , order support widen specification limit , study perform . The target formulation use representative commercial formulation . Other objective study 1 ) compare relative bioavailability paliperidone ER formulation slow , target , fast vitro release rate paliperidone IR formulation ; 2 ) explore vitro vivo correlation ( IVIVC ) paliperidone ER formulation ; 3 ) evaluate safety tolerability different paliperidone ER formulation .</brief_summary>
	<brief_title>A Pharmacokinetic Study Relative Bioavailability Paliperidone ER Formulations With Different Release Profiles Comparison Paliperidone IR</brief_title>
	<detailed_description>This randomize , open-label , 4-way crossover , single dose study healthy male volunteer evaluate pharmacokinetic profile paliperidone ER tablet slow , target , fast vitro release rate paliperidone IR . The study consist 21 day screen phase , open-label treatment phase consist 4 single-dose treatment period ( IR , slow , fast , target formulation ) , end-of-study early withdrawal phase . A 10- 21 day washout period ( i.e. , &gt; 5 time half-life ) separate study drug administration ( i.e. , open label treatment period ) . In first period , volunteer give 1-mg dose paliperidone IR solution , administer single oral dose fast condition ( Treatment A ) . On Day 1 Period 2 , prior study drug administration , volunteer randomly assign 1 6 possible treatment sequence ensure receive follow treatment , one period : 12-mg paliperidone ER tablet target vitro release fast condition ( Treatment B ) ; 12-mg paliperidone ER tablet slow vitro release fast condition ( Treatment C ) ; 12-mg paliperidone ER tablet fast vitro release fast condition ( Treatment D ) . In treatment period , volunteer enter study center least 10 hour study drug administration Day 1 remain collection 96 hour pharmacokinetic sample Day 5 investigator considers volunteer ready discharge . It expect difference vitro release rate affect relative bioavailability paliperidone vivo . Safety tolerability different paliperidone ER formulation monitor throughout study . Single oral dos paliperidone ER 12 mg tablet different release rate ( target , fast , slow ) ; single oral dose paliperidone IR 1 mg</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Must agree use efficient method birth control deem appropriate investigator donate sperm study 3 month receive last dose study drug Body mass index ( weight [ kg ] /height [ m2 ] ) 18 30 kg/m2 ( inclusive ) , body weight less 50 kg Blood pressure ( volunteer supine 5 minute ) 100 140 mmHg systolic , inclusive , 50 90 mmHg diastolic . Pulse rate measure 60 second 40 100 beat per minute ( bpm ) Nonsmoker History current significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude volunteer History presence circumstance may increase risk occurrence torsade de pointes and/or sudden death association use drug prolong QTc interval , include : bradycardia ( heart rate &lt; 40 bpm ECG ) , clinically significant abnormality ECG , demonstration repeat prolonged QTcF &gt; 450 m ( QTc interval correct heart rate use Fridericia 's formula ) , measure one ECG ( either screening , prior medical record ) The following cardiac condition : sick sinus syndrome , complete AV block , congestive heart failure , polymorphic ventricular tachycardia Clinically relevant hypocalcemia , hypokalemia hypomagnesemia Presence congenital prolongation QT interval ( RomanoWard Syndrome , Jervell LangeNielsen syndrome ) History cancer , exception basal cell carcinoma : Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission study center , opinion investigator Clinically significant abnormality physical examination , opinion investigator At screening , sign orthostatic hypotension define decrease systolic ( &gt; 20 mmHg ) diastolic ( &gt; 10 mmHg ) blood pressure stand least 2 minute , associate increase pulse rate &gt; 15 bpm compare supine measurement Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol ( acetaminophen ) ibuprofen , within 14 day first dose study drug schedule</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Paliperidone ER</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood disorder</keyword>
</DOC>